Table 1.
Characteristics of COVID-19 vaccination encounters by vaccine brand and dose number.
| AstraZeneca | Moderna | Novavax | Pfizer | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose 1 | Dose 2 | Dose 3 | Booster | Dose 1 | Dose 2 | Dose 3 | Booster | Dose 1 | Dose 2 | Dose 3 | Booster | Dose 1 | Dose 2 | Dose 3 | Booster | |
| n | 4076 | 25,587 | 156 | 661 | 29,870 | 37,508 | 2218 | 67,637 | 1386 | 1248 | 14 | 681 | 12,538 | 11,571 | 2889 | 58,693 |
| Vaccinated age (years), median (Q1, Q3) | 47 (32, 63) |
45 (29, 63) |
59 (40, 68) |
58 (42, 67) |
32 (20, 48) |
32 (19, 47) |
53 (36, 65) |
47 (32, 62) |
41 (31, 55) |
43 (32, 58) |
61 (51.5, 74) |
48 (34, 62) |
11 (8, 23) |
13 (9, 31) |
42 (30, 58) |
39 (27, 57) |
| Sex | ||||||||||||||||
| Female | 1293 (31.7) |
7725 (30.2) |
58 (37.2) |
218 (33.0) |
10,850 (36.3) |
12,939 (34.5) |
812 (36.6) |
24,328 (36.0) |
439 (31.7) |
430 (34.5) |
4 (28.6) |
265 (38.9) |
3745 (29.9) |
3609 (31.2) |
940 (32.5) |
20,323 (34.6) |
| Male | 1661 (40.8) |
9628 (37.6) |
49 (31.4) |
205 (31.0) |
11,609 (38.9) |
13,822 (36.9) |
659 (29.7) |
19,635 (29.0) |
353 (25.5) |
327 (26.2) |
3 (21.4) |
211 (31.0) |
3643 (29.1) |
3582 (31.0) |
783 (27.1) |
16,014 (27.3) |
| Not recorded | 1122 (27.5) |
8234 (32.2) |
49 (31.4) |
238 (36.0) |
7411 (24.8) |
10,747 (28.7) |
747 (33.7) |
23,674 (35.0) |
594 (42.9) |
491 (39.3) |
7 (50.0) |
205 (30.1) |
5150 (41.1) |
4380 (37.9) |
1166 (40.4) |
22,356 (38.1) |
| Chronic medical condition/s | 271 (15.6) |
1163 (12.4) |
19 (22.6) |
62 (20.4) |
1328 (9.7) |
1243 (8.9) |
357 (31.1) |
4051 (12.8) |
100 (15.6) |
84 (15.7) |
3 (50.0) |
63 (19.4) |
260 (4.5) |
221 (5.0) |
300 (21.4) |
2716 (10.9) |
| History of anaphylaxis | 51 (2.9) |
140 (1.5) |
4 (4.8) |
12 (3.9) |
331 (2.4) |
321 (2.3) |
27 (2.3) |
624 (2.0) |
20 (3.1) |
15 (2.8) |
0 (0.0) |
13 (4.0) |
105 (1.8) |
99 (2.2) |
18 (1.3) |
444 (1.8) |
| Pain/fever medicine pre vaccination | 597 (34.5) |
1793 (19.1) |
13 (15.5) |
48 (15.8) |
3082 (22.6) |
5750 (41.2) |
332 (28.9) |
10,235 (32.4) |
111 (17.3) |
120 (22.4) |
3 (50.0) |
61 (18.8) |
1322 (22.7) |
1087 (24.4) |
381 (27.2) |
7189 (28.8) |
| Day 3 Survey | ||||||||||||||||
| Sent | 3901 (95.7) |
25,407 (99.3) |
154 (98.7) |
650 (98.3) |
29,489 (98.7) |
37,354 (99.6) |
2133 (96.2) |
66,326 (98.1) |
1338 (96.5) |
1214 (97.3) |
11 (78.6) |
614 (90.2) |
12,398 (98.9) |
11,345 (98.0) |
2776 (96.1) |
57,362 (97.7) |
| Responded | 1732 (44.4) |
9410 (37.0) |
84 (54.5) |
304 (46.8) |
13,647 (46.3) |
13,944 (37.3) |
1149 (53.9) |
31,592 (47.6) |
643 (48.1) |
536 (44.2) |
6 (54.5) |
324 (52.8) |
5818 (46.9) |
4460 (39.3) |
1399 (50.4) |
24,976 (43.5) |
| Responded age (years), median (Q1, Q3) | 51 (35, 64) |
53 (33, 64) |
59.5 (50.25, 66.25) |
60 (48, 68) |
34 (19, 50) |
35 (18, 51) |
56 (42, 67) |
52 (35, 64) |
43 (32, 57) |
46 (35, 59) |
68.5 (57.25, 76.75) |
52.5 (40, 67) |
10 (8, 17) |
11 (8, 27) |
48 (34, 61) |
45 (29, 60) |
| Reported adverse event | 1010 (58.3) |
2196 (23.3) |
19 (22.6) |
71 (23.4) |
5423 (39.7) |
9120 (65.4) |
704 (61.3) |
17,292 (54.7) |
222 (34.5) |
315 (58.8) |
0 (0.0) |
93 (28.7) |
1516 (26.1) |
1408 (31.6) |
587 (42.0) |
10,391 (41.6) |
| Medication to relieve symptoms | 634 (63.0) |
1183 (54.2) |
13 (68.4) |
35 (49.3) |
2555 (47.4) |
6089 (67.1) |
446 (63.6) |
10,497 (61.0) |
110 (50.0) |
185 (59.3) |
0 (0.0) |
46 (49.5) |
724 (48.0) |
774 (55.3) |
313 (53.5) |
5874 (56.9) |
| Reported medical review or advice a | 81 (4.7) |
107 (1.1) |
0 (0.0) |
6 (2.0) |
225 (1.6) |
648 (4.6) |
13 (1.1) |
554 (1.8) |
21 (3.3) |
16 (3.0) |
0 (0.0) |
12 (3.7) |
57 (1.0) |
73 (1.6) |
15 (1.1) |
344 (1.4) |
| Phone advice | 36 (46.2) |
30 (34.5) |
0 (0.0) |
2 (50.0) |
86 (42.6) |
238 (40.4) |
2 (28.6) |
184 (41.3) |
8 (44.4) |
8 (50.0) |
0 (0.0) |
5 (45.5) |
21 (42.9) |
29 (44.6) |
3 (27.3) |
111 (39.6) |
| Care from a GP | 38 (48.7) |
52 (59.8) |
0 (0.0) |
1 (25.0) |
97 (48.0) |
294 (49.9) |
5 (71.4) |
221 (49.7) |
10 (55.6) |
9 (56.2) |
0 (0.0) |
4 (36.4) |
26 (53.1) |
28 (43.1) |
8 (72.7) |
144 (51.4) |
| Emergency department visit | 15 (19.2) |
16 (18.4) |
0 (0.0) |
1 (25.0) |
45 (22.3) |
119 (20.2) |
1 (14.3) |
71 (16.0) |
3 (16.7) |
2 (12.5) |
0 (0.0) |
2 (18.2) |
12 (24.5) |
12 (18.5) |
0 (0.0) |
41 (14.6) |
| Day 42 Survey | ||||||||||||||||
| Sent | 1731 (42.5) |
9399 (36.7) |
82 (52.6) |
236 (35.7) |
13,600 (45.5) |
13,875 (37.0) |
1052 (47.4) |
27,656 (40.9) |
469 (33.8) |
184 (14.7) |
0 (0.0) |
45 (6.6) |
5654 (45.1) |
2856 (24.7) |
1269 (43.9) |
20,652 (35.2) |
| Responded | 999 (57.7) |
5487 (58.4) |
47 (57.3) |
151 (64.0) |
7482 (55.0) |
7574 (54.6) |
687 (65.3) |
15,976 (57.8) |
300 (64.0) |
150 (81.5) |
0 (0.0) |
35 (77.8) |
2911 (51.5) |
1616 (56.6) |
779 (61.4) |
11,135 (53.9) |
| Responded age (years), median (Q1, Q3) | 58 (41, 65) |
60 (39, 66) |
63 (57, 69.5) |
62 (56, 69) |
37 (20, 53) |
39 (19, 55) |
59 (47.5, 68) |
56 (40, 66) |
47.5 (34, 60) |
48 (37.25, 57.75) |
- | 58 (42, 68) |
10 (8, 13) |
12 (9, 35) |
52 (40, 64) |
51 (35, 63) |
| Reported new illness | 40 (4.0) |
113 (2.1) |
2 (4.3) |
5 (3.3) |
192 (2.6) |
213 (2.8) |
20 (2.9) |
300 (1.9) |
19 (6.3) |
3 (2.0) |
0 (0.0) |
3 (8.6) |
62 (2.1) |
33 (2.0) |
13 (1.7) |
164 (1.5) |
| Tested COVID-19 positive | 9 (0.9) |
36 (0.7) |
3 (6.8) |
3 (4.3) |
24 (0.3) |
72 (1.0) |
27 (4.4) |
273 (2.8) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
199 (7.6) |
37 (5.1) |
29 (4.5) |
219 (3.4) |
All reported as n (%). a Respondents could select multiple levels of medical review or advice. This shows engagement with the health system, not the highest level of care sought. Proportions add to more than 100%. Age is shown overall, at day 3 and at day 42 for comparison of those vaccinated with those who responded.